Highly effective treatments for HIV, including drug-resistant strains
Ultrapotent Inhibitors of Wild-type and Multi-drug Resistant HIV
Researchers are developing next-generation islatravir-based drugs to strongly block HIV, including strains that resist current medicines, for people living with HIV.
Quick facts
| Grant type | R37 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Emory University NIH-funded |
| Lab location | 1 site (Atlanta, United States) |
| Project ID | NIH-11251940 on NIH RePORTER |
What this research studies
You should know that scientists will study how second-generation versions of islatravir stop HIV and why some viruses become resistant. They will use lab experiments with HIV samples and human-derived cells to map mechanisms of action, resistance, and hypersusceptibility. The team aims to use those findings to design long-acting, safer drug combinations with existing antivirals. Results could guide future clinical testing and better treatment options for patients with difficult-to-treat HIV.
Who could benefit from this research
Good fit: Ideal candidates are people living with HIV, especially those whose virus has become resistant to current drugs or who want long-acting treatment options.
Not a fit: People without HIV or those whose infection is stable and well controlled on current therapies are unlikely to gain direct benefit from this project.
Why it matters
Potential benefit: If successful, this work could lead to longer-lasting, safer HIV treatments that work against drug-resistant virus.
How similar studies have performed: Islatravir has already shown strong antiviral activity and is in phase 3 trials, so this approach builds on promising results though the new compounds remain experimental.
Where this research is happening
Atlanta, United States
- Emory University — Atlanta, United States (Active)
Researchers
- Principal investigator: Sarafianos, Stefan G — Emory University
- Study coordinator: Sarafianos, Stefan G
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.